Article Text

AB0414 Real-World Cost of Treating Inadequate Responders to Anti-Tumour Necrosis Factor Therapy
  1. E. Thomson1,
  2. A. Nadkarni2,
  3. M. Brouillette1,
  4. S. Johnston1
  1. 1Truven Health Analytics, Bethesda
  2. 2Bristol-Myers Squibb, Plainsboro, United States


Background Individuals with rheumatoid arthritis (RA) receiving anti-tumour necrosis factor-α (anti-TNF) therapy may have an inadequate response (IR) to first-line treatment. Among those patients for whom treatment fails, little is known about the associated costs of treatment or the subsequent proportion with an IR to a second-line anti-TNF treatment.

Objectives This study quantified the RA-related healthcare cost of treating patients who respond inadequately to anti-TNF therapy using an adaptation of a published administrative claims-based algorithm to identify IR. We examined the probability of IR to first- and second-line anti-TNF biologics, and assessed RA-related healthcare costs among patients with an IR to first- or second-line treatments.

Methods This was a retrospective, observational cohort study based on administrative claims data. Adult (aged ≥18 years) patients with RA initiating anti-TNF therapy between 1 January 2009 and 31 December 2013 were included in the analysis. Patients were required to have continuous insurance enrolment for 12 months before initiating anti-TNF therapy, and no treatment with any biologics during this period. Patients who experienced an IR to first-line anti-TNF therapy and were treated with second-line anti-TNF therapy were analysed as a sub-sample. Variable-length follow-up was measured for both the first- and second-line treatments, beginning with initiation of an anti-TNF and continuing until one of the following events: use of a biologic that is different from the initiated anti-TNF, disenrolment from health insurance or reaching the study end date of 31 December 2013. IR was defined as a composite of discontinuation or switch of the initiated anti-TNF, anti-TNF dose escalation, initiation of a new non-biologic DMARD, new/increased oral glucocorticoid (OGC) use/dose or receiving ≥2 injections of glucocorticoid (IGC). Kaplan–Meier analysis was used to calculate probability of IR over time. RA-related healthcare utilization and costs were expressed in per-patient per-month (PPPM) units and corresponded to medical claims with an International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis code for RA, the initiated anti-TNF and non-biologic DMARDs.

Results A total of 26,785 patients met our inclusion criteria for the first-line analysis; 4638 for the second-line analysis. Mean follow-up time was 525 days for first line and 383 days for second line; Kaplan–Meier-estimated probabilities of IR were 67% at 6 months, 82% at 12 months and 91% at 24 months for first line; 77%, 89% and 95% at 6, 12 and 24 months for second line. In both lines, the primary reason for IR was discontinuation of initiated anti-TNF (52–61% of patients), followed by: 2+ IGC (30–33%); switch of initiated anti-TNF (23–34%); initiation of a new non-biologic DMARD (14–27%); anti-TNF dose escalation (15–19%); new/increased OGC use/dose (13–15%). Average RA-related PPPM costs were $3883 (SD $10,697) for patients with an IR to first-line therapy and $6831 (SD $32,849) for patients with an IR to second-line therapy.

Conclusions In this retrospective study using real-world data, a high proportion of patients with RA experienced an event indicative of IR to first- or second-line anti-TNF treatment. The RA-related healthcare costs of treating patients with IR were substantial.

Disclosure of Interest E. Thomson Grant/research support from: Bristol-Myers Squibb, Employee of: Truven Health Analytics, A. Nadkarni Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, M. Brouillette Grant/research support from: Bristol-Myers Squibb, Employee of: Truven Health Analytics, S. Johnston Consultant for: Bristol-Myers Squibb, Employee of: Truven Health Analytics

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.